PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.79%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.36%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
-46.43%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-309.91%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-309.91%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-2284.85%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-2260.25%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-2260.25%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.61%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.61%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
104.19%
OCF growth of 104.19% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
80.26%
FCF growth of 80.26% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
946.12%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.05%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
538.59%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.67%. Joel Greenblatt might see a short-term competitive advantage at play.
-84.89%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
65.84%
OCF/share CAGR of 65.84% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
261.74%
3Y OCF/share growth of 261.74% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-5501.82%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-4443.43%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 9.81%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-289.78%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 11.84%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
3122.11%
Equity/share CAGR of 3122.11% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
403.50%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 11.22%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
-8.22%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 5.43%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.56%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
2.73%
Inventory growth of 2.73% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
13.71%
Asset growth of 13.71% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.38%
BV/share growth of 5.38% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
29.90%
Debt growth of 29.90% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
88.66%
R&D growth of 88.66% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
18.88%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.